Detailed data from the Phase III part of FRUSICA-2, the China registration study of fruquintinib in combination with sintilimab (Tyvyt, a PD-1 inhibitor) as second-line (2L) treatment for locally advanced or metastatic renal cell carcinoma (RCC), will be presented at ESMO 2025. The data provide insights into the impressive and significant magnitude of benefit observed across the primary endpoint of PFS (progression free survival), as well as secondary endpoints including ORR (objective response rate) and DoR (duration of response). The combination was tolerable, and the safety profile was
consistent with each individual treatment. This indication is currently under China NMPA review, following filing acceptance in June 2025.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
